To be eligible for the implant, patients must:
- Be 65 years of age or older
- Have retinal findings of geographic atrophy or disciform scar with foveal involvement
- BCDVA of 20/160-20/800
- Phakic in one eye
The FDA clinical studies involving 28 leading ophthalmic centers and over 225 patients demonstrated statistically significant and clinically meaningful results for improved visual acuity and quality of life for patients with end-stage AMD. 90% of telescope implant patients improve 2 lines ETDRS and 60% achieve 3 lines ETDRS, and demonstrated improved quality of life on a National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25), reporting that they are less limited and less dependent on others in their activities related to vision.
We are pleased to be the only center in New Mexico offering this new treatment program.